Prostaglandins and fibroblast functions in vitro

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Secondary embryonic mouse fibroblasts synthesize primarily E-type prostaglandins (PGs), with lower levels of PGF2 alpha and no PGI2.
• These fibroblasts possess an adenylate cyclase system responsive to E-type PGs, particularly PGE1.

Purpose of the Study:

• To investigate the relationship between prostaglandin (PG) synthesis, cyclic adenosine monophosphate (cAMP) levels, and glycosaminoglycan (GAG) biosynthesis in mouse fibroblasts.
• To explore the impact of antirheumatic agents on these cellular processes and fibroblast proliferation.

Main Methods:

• Measurement of PG synthesis (PGE, PGF2 alpha, PGI2).
• Assay of adenylate cyclase activity and cAMP levels in response to PGE1.
• Quantification of GAG biosynthesis and analysis of carbohydrate spectrum.
• Assessment of fibroblast proliferation rates.
• Evaluation of the effects of steroidal and non-steroidal antirheumatic agents.

Main Results:

• PGE1 dose-dependently increases cAMP levels, stimulating GAG biosynthesis and PG formation without altering GAG quality.
• Antirheumatic agents modulate basal or PGE1-stimulated cAMP levels and GAG biosynthesis, independent of their PG formation inhibitory action.
• PGE1 inhibits fibroblast proliferation; prolonged reduction in endogenous PG formation leads to compensatory cell sensitivity.

Conclusions:

• E-type PGs and cAMP play a crucial role in regulating GAG biosynthesis and fibroblast proliferation.
• Antirheumatic drugs can influence fibroblast function through mechanisms beyond PG synthesis inhibition.
• Fibroblast responses to altered PG levels involve adaptive changes in cell sensitivity and signaling pathways.